Ultragenyx Pharmaceutical Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Ultragenyx Pharmaceutical develops and sells treatments for rare and ultra-rare genetic diseases, including approved therapies for conditions like Hypophosphatasia and Wolman disease, alongside a pipeline of gene therapy and other candidates targeting metabolic and skeletal disorders.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Horn HowardChief Financial Officer | Sell | $108K | 7,066at $15.27 | Oct 15, 2026 |
| Huizenga Theodore AlanSVP, Chief Accounting Officer | Sell | $17K | 1,283at $13.57 | Sep 15, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
| Member | Chamber | Type | Amount | Date |
|---|---|---|---|---|
| Gilbert CisnerosCA31 | House | Buy | $1,001 - $15,000 | Sep 29, 2026 |
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable RARE activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.